Effects of Platelet Rich Plasma Injections on Biomarkers After Anterior Cruciate Ligament Tears
Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Rupture
About this trial
This is an interventional prevention trial for Anterior Cruciate Ligament Tear
Eligibility Criteria
Inclusion Criteria:
- No history of previous traumatic ipsilateral knee injury
- Bone bruise visualized on MRI
- No clinical evidence of posterior cruciate ligament injury with no more than grade 1 medial or lateral collateral ligament injury
Exclusion Criteria:
- Patients without a palpable knee effusion
- An injury occurring more than 10 days before enrollment
- Previous ipsilateral knee surgery
- Intra-articular cortisone or platelet rich plasma injection into either knee within 3 months of injury
- Participation in another clinical drug trial within the 4 weeks before injury
- A history of any inflammatory disease or immune-comprised
Sites / Locations
- Andrews Institute for Orthopaedics & Sports MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Control Group
Experimental Group
The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee. At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection. A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).